The Chicago Athenaeum: Museum of Architecture has announced its 60th annual Good Design Awards, which honor "quality design of the highest form, function, and aesthetic." Guess which paragon of contemporary design won an award this year? An insulin needle. Called the NovoTwist and made by Novo Nordisk for use with insulin pens, this marvel of design has a bayonet fitting that allows "just twist" attachment and detachment to compatible pens, and an audible and tactile "click" that confirms attachment of the needle.
Working toward the goal of unifying patients' diabetic treatment information in a single place, the PositiveID Corporation hopes to patent a new device that monitors insulin pens. The Insulin Tracker would attach to a user's insulin pen and record the times and amounts of injections. That information would then be sent to a database that allows for comprehensive monitoring. Insulin pens come in disposable and cartridge-replaceable flavors; the tracker can be moved easily from one pen to another.
Physicians who treat people with type 2 diabetes face difficult choices when selecting the best medical therapy for each patient. The decision process is further complicated by the fact that because type 2 diabetes is a progressive disease, therapeutic agents that were initially successful may fail five or ten years later.
Novo Nordisk has redesigned the FlexPen®, the number one selling pre-filled insulin pen in the world, to not only require less force when pushing the button to inject insulin, but also to clearly identify each type of insulin with prominent color branding. The FlexPen® is available with three Novo Nordisk insulin products: Levemir® (insulin detemir [rDNA origin] injection); NovoLog® (insulin aspart [rDNA origin] injection); and NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]).
The stock of Byetta manufacturer Amylin Pharmaceuticals has lost more than half of its value over the past eight weeks, thanks to FDA concerns that the type 2 treatment may be connected with the deaths from acute pancreatitis of six Byetta users. Although the FDA has not proven a direct association between fatal pancreatitis and the use of Byetta, Amylin's stock has fallen nevertheless.
Nassau University Medical Center said it had underestimated the number of diabetes patients potentially exposed to reused insulin pens and would be sending letters to at least 840 of them, instead of 185, urging them to be tested for hepatitis C and B and HIV.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.